biotech event brussels, 28th of june 206 - ibm · biotech event brussels, 28th of june 206 ... an...
Post on 21-Aug-2018
215 Views
Preview:
TRANSCRIPT
IBM Healthcare & Life Science Group
®
Biotech Event
Brussels, 28th of June 206
Juergen GoertlerDeepComputing and Infrastructure SolutionsIBM BeNeLuxgoertler@de.ibm.com
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Agenda10:00 - 10:30 hours Registration customers and welcome
10:30 – 11:15 hours Informatics tools to manage the data explosion and secure your corporate knowledgeSpeaker: Rene Simons of Waters N.V.
11:15 - 12:00 hours Software Tools for Data Analysis in R&DSpeaker: Benjamin Damien of BioXpr
12:00 – 12:45 hours LIMS Systems Speaker: Kevin Jones of Genologics
13:30 - 14:15 hours Underlaying IT architectures Speaker: Nicky Hekster of IBM
14:15 - 15:00 hours Newest Processor Developments, Speaker: Jan De Bondt of AMD
15:00 - 15:15 hours Break
15:15 - 16:00 hours How to approach a project Speaker: Luc Ducazu of Fit IT
16:00 - 16:45 hours LifeSciences and IBM, Speaker: Jacky Boonen of IBM
12:45 - 13:30 hours Lunch
16:45 hours Drinks
IBM Healthcare & Life Science Group
®
Biotech Event
Brussels, 28th of June 206
Jacky BoonenIBM Healthcare & Lifesciences Solution ExecutiveIBM BeNeLux Jacky.boonen@be.ibm.com
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Challenges in the Industry Integration, Collaboration, Data Mining, Speed to Market, Segmentation …
The change in customer demands,
technological innovations and
government regulations is
increasingly sudden and dramatic
Continuous Discontinuities
CompetitiveDarwinism
Due to increasingly transparent markets,
competitive intensity is growing in severity as existing players and
new entrants scramble to provide value to
customers
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Challenges in the Industry Security, Efficiency, Cost Savings, Streamlining, Information Management ….
Unrelenting Financial Pressures
UnpredictableThreats
The growth and predictability of
revenues and margins becomes even more challenging due to
economic uncertainties and demanding
investors
Pervasive dangers become real and
prevalent as global firms see increased exposure to natural disasters, unstable
geopolitics and other market shocks
CAGR of 5.2%
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Pharmaceutical Product Development Cycle
5,000–10,000Screened
5,000–10,000Screened
250Enter Preclinical
Testing
250Enter Preclinical
Testing
5Enter
Clinical Testing
5Enter
Clinical Testing
1Approved
by the FDA
1Approved
by the FDA
Net Cost: $802 million invested over 15 years
16
14
12
10
8
6
4
2
0Discovery(2-10 Years)
Preclinical TestingLaboratory andAnimal Testing
Years
Phase I20-80 Healthy VolunteersUsed to Determine Safety
And Dosage
Phase III1,000-5,000 PatientVolunteers Used to
Monitor Adverse Reactionsto Long-term Use
Phase II100-300 Patient VolunteersUsed to Look for Efficacyand Side Effects
FDA Review/Approval
Compound Success Rates by Stage
Source: Tufts Center for the Study of Drug Development
AdditionalPost-marketing
Testing
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Targeted Treatment Solutions Will become the major revenue earners of the future but will requires re-invention across the value chain
Today
1980 1990 2000 2010 2020
Phar
ma
Rev
enue
s ($
)
Traditional Products High Density
Products
Gene-based Therapies
Targeted Treatment Solutions
Today
1980 1990 2000 2010 2020
Phar
ma
Rev
enue
s ($
)
Traditional Products High Density
Products
Gene-based Therapies
Targeted Treatment Solutions
SupportFunctions
Multiple Supply Chain Models with Increased Emphasis on
Biologics
New Disease-Led Approach with Focus on
Clinical Support Package
Adaptive Trials, Continuous Marketing
Application and In-Life Testing
Outcome Oriented
Marketing and Electronic
Medical Records
Smaller and Smarter Sales
Force with Integrated
Media
Human Resources, Finance & Accounting, Information Technology
Variable Service Levels, Process Outsourcing
DeliveryDiscovery Development Manufacture Marketing Sales
Information Based Medicine
Invest NewProducts
Traditional ProductsHi-density ProductsTargeted
Treatment Solutions
Accurate Assessment of the Threshold of Innovation
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Building Disease, Target & Biomarker Knowledge
Transforming into a Biology Centric Discovery Process
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Life sciences Ecosystem
Basic Research
Labs
Pharma Biotechs &
CRO
Analytical Instruments, Diagnostics & Medical Devices
Academic Medical Research Centers
Integrated Care Delivery Networks
Community Hospitals and Practices
Payers: Private, Government, Employers
Life Sciences
Healthcare Providers
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Evolution of Medicine
Personalized Health Care
Translational Medicine
Health Care Today Digital Imaging
Episodic Treatment Electronic Health Records Artificial Expert Systems
Clinical Genomics
Genetic Predisposition Testing
Molecular Medicine
CA Diagnosis
Pre-symptomatic Treatment
Lifetime Treatment
Evolutionary Practices
Rev
olut
iona
ry T
echn
olog
y
Automated Systems
Non-specific (Treat Symptoms)
Information Correlation
1st Generation Diagnosis
Organized(Error Reduction)
Personalized(Disease Prevention)
Dis
trib
uted
Hig
h-Th
roug
hput
Ana
lytic
s
Data and Systems Integration
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Storage needs are increasingPharma 2010 IT > Discovery > Data Volumes
Genebank has seen an exponential growth in data generated from new advances in laboratory automation and techniques over the last ten years
Data as at February 2003. Source: www.ncbi.nih.gov/genebank/genbankstats.html.Year
Exponential Increase in Base Pairs and Sequences
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
22,000
24,000
26,000
28,000
30,000
Year 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Bas
e Pa
irs (m
illio
ns)
0
2
4
6
8
10
12
14
16
18
20
22
24
Sequ
ence
s(m
illio
ns)
Base Pairs Sequences
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Sequence assembly algorithms
Data miningand PatternDiscovery
Molecular modeling andStructure prediction
Complex celland organsimulation
# SEQLET # SEQLET 1 G..G.GK[STG]TL2 H.....HRD.K..N3 SGG[QEMRY]..R[VLIA].[IGLMV]R.L4 V.I.G.G..G...A6 G.GLGL.I...
Life Sciences Informatics drives High End Computing
HTS data
The Challenge: data complexity augments
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Pharma IT funding trends : IT spending is on the rise…And is forecast to continue rising
$3.406
$3.879
$4.391
$4.877
$5.505
$3.015
$0
$1.000
$2.000
$3.000
$4.000
$5.000
$6.000
2000 2001 2002 2003 2004 2005
YearU
S Ph
arm
a In
dust
ry T
otal
Spe
nd (U
S$ m
illio
ns)
CAGR = 12.8%
Source: “US Pharmaceutical Industry: IT spending Forecast.”Gartner DataQuest, July 2001
IT Spend as % of Revenue
4,02%3,77%
3,34%
2,90%
2,58%
0,00%
0,50%
1,00%
1,50%
2,00%
2,50%
3,00%
3,50%
4,00%
4,50%
1997 1998 1999 2000 2001
© Copyright 2002 META Group
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Drug discovery - summary of key features and implications
Pharma 2010 IT > Discovery > Key Features
© 2004 IBM Corporation
IBM Healthcare & Life Science GroupIBM Organisation
SMEPublicSector
HealthHealth
DistribFinanceassurance
Telecom Industry
Systems Sales Material
Software Software
Personnal computing PC
IBM Global financing Financing
IBM Global Services infrastructure
IBM Business Consulting Services Industry skills
Life SciencesHealth
PharmaBiotech
Diagnostic
R&D CenterIBM
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
IBM’s Commitment to Healthcare & Life Sciences
Designated Life Sciences an IBM Emerging Business Oppty (EBO) Unit - Spring 2000
IBM Business Consulting ServicesPwC Consulting acquisition
Pharma 2010: The Threshold of Innovation
Strategic partnerships with industry leaders
Created IBM Healthcare & Life Sciences (2004)
Designated Information Based Medicine an IBM EBO in 2004
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
IBM Research: 8 sites, >3000 scientists,>38000 patents and …. 5 Nobels
Almadenemployees: 400computer science, database, user interface, web software, storage systems software & technology, physical sciences, materials science, nanotechnology, life sciences, DiscoveryLink, services research
Haifaemployees: 280VLSI design, verification technology, storage subsystems incl medical, e-business and security, computer systems, programming languages and environments, advanced applications, applied mathematics, multimedia, and service technologies.
Tokyo employees: 190software technology, systems technology, pervasive computing, Internet technology and applications, deep computing, 3D rendering
Beijing
employees: 90language processing, speech & handwriting recognition, pervasive computing, mobile computing, multimedia, and e-business technologies & solutions
Austin
employees: 40high performance/low power VLSI design and tools, system-level power analysis, and new system architectures
Watsonemployees: 1,680semiconductors, physical & computer sciences, life sciences and mathematics
Zurichemployees: 210communication systems, computer science, selected science and technology projects, and industry solutions and services research
employees: 70deep computing, bioinformatics, functional genomics commerce, media mining, fingerprint matching, speech recognition, weather forecasting and wireless networks
India
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
http://www.research.ibm.com/compsci/compbio/index.html
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Distinctive Point of View on industry issues…
An Industrial Revolution in R&D
The Future of Clinical Trials-How Genomics, Proteomics and
Technology are Changing the Clinical Development Process
Silicon Rally:The Race to e-R&D
Realising the Full Rewards of EDC
Pharma 2010: The Threshold of Innovation
Pharma 2005Marketing to the
Individual
IBM Business Consulting Services continues to invest in research into the future of the pharmaceutical industry.
The Pharma 2005 series, published in 1998 and 1999, predicted the falling shareholder returns and consolidation of the industry that have occurred over the last few years.
http://www.ibm.com (search on “pharma 2005”)
We have recently published the follow up, Pharma 2010: The Threshold of Innovation, that forecasts a slow down in growth for the industry and describes a new industry model based on Targeted Treatment Solutions.
http://www.ibm.com/services/pharma2010
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
IBM’s HC&LS focus is Infrastructure, Middleware and services
IBM and Partners provide hardware, software, and services that enhance discovery and development efforts
ADD OTHER LOGOS
e-business infrastructure
Industry specific applications
Content
Tools
IBM Life Sciences Framework
High Performance Information Infrastructure
Partners
Deep computing and storage/data management infrastructure
Service
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
A large panel of partners and scientific codes
© Copyright by IBM Corp.
Gaussian
DiscoverCHARMm
DMOL
Open Force Field (OFF)
Polymorph PredictorGamess
Spartan
AmberQ-Chem
Jaguar
NWChemetc.....
BLASTFASTA
ClustalW
Smith-Waterman
+ 220 applications
PSI-BLAST
BLAT
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
IBM supports WW standards…
… and open-source.
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Scope of Pharma R&D Services
eDev
elop
men
t Stra
tegy
, arc
hite
ctur
ean
d Bu
sine
ss C
ase
Performance Improvement
Stra
tegy
Tech
nolo
gyPr
oces
s
DesignAdvise Build/Implement
Operate
Architecture and User Requirements Definition and Implementation eg EDC, e-Dossier, Archiving
Pro
cess
Re-
desi
gn
Organisation Re-design
Hos
ting,
Hel
p D
esk
and
Har
dwar
e D
eplo
ymen
t eg
EDC
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
High Performance Computing
Storage, Managed Storage Services
Integrated Technology Services
Tivoli
Services/e-sourcing
Bio-Grids
High Performance Integrated Information Infrastructure (HPIII) for drug discovery and research
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
IBM Websphere information integrator TM , DB2TM
Knowledge Management solution, Lotus
Services
Data and Knowledge Management solutions for scientific collaboration
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
Introduction into the IBM SCORE solutionIBM Solution for Compliance in a Regulated Environment (IBM SCORE) is a flexible and easy to configure regulatory compliancesolution
Provides the core information lifecycle and process management, security, and auditing functionality required to comply with regulations.
Allows the integration of document management and compliance systems with operational systems.
Collaborative and intuitive portal environment providing configurable out of the box functions. Flexible to support both regulated as non-regulated content.
Full blown eCTD solution, full lifecycle management of submissions and its content
Complete solution: combining best practices in software and services, allowing a fast track validated implementation including pre-configurations and accelerators
»»»» Collaboration
Application Integration
Business Process
Management
Data and Document
Management
eCTD Management
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
IBM SCORE: Ability to anticipate and respond on changing Life Sciences compliance business demands
SCORE is a life sciences focused solution which:
Supports key industry regulations and processes, such as GXP, 21CFR11
Flexible to support all processes across the Life Sciences value chain
Research SalesDevelopment MarketingManufacture
Electronic Submissions
Clinical Trial Management
Knowledge Management
GMP Documentation
Quality Management
Packaging & Labeling
Medical Information
Marketing & Promotion Materials
Web Content Management
Sales Enablement
New Disease-Led Approach
Increasing Collaboration
New Development
Approach, Adaptive and In-
Life Trials, Rolling Dossier
Multiple Supply Chain
Models
Improved Compliance
Outcome Oriented
Marketing, EMR
Smaller and Smarter Sales
Force and Integrated
Media
Closer relationships between payers, providers and regulators
Research SalesDevelopment MarketingManufacture
Electronic Submissions
Clinical Trial Management
Knowledge Management
GMP Documentation
Quality Management
Packaging & Labeling
Medical Information
Marketing & Promotion Materials
Web Content Management
Sales Enablement
New Disease-Led Approach
Increasing Collaboration
New Development
Approach, Adaptive and In-
Life Trials, Rolling Dossier
Multiple Supply Chain
Models
Improved Compliance
Outcome Oriented
Marketing, EMR
Smaller and Smarter Sales
Force and Integrated
Media
Closer relationships between payers, providers and regulators
© 2004 IBM Corporation
IBM Healthcare & Life Science Group
IBM defines Information Based Medicine as the process of transforming existing medical and pharmaceutical practices with knowledge generated from the integration and analysis of diverseclinical and biomedical data
Biomedical
Image Data
Biobanks,AMRC’s
BioPharmaR & D
Healthcare Delivery
Clinical
Data
Genomic
Data
Epidemiological
Data
Phenotype Genotype Population
PersonalizedMedicine
Information Based Medicine
BRD PGx CDI BRD
PGx
CDI
Basic Research /Discovery
Pharmaco-Genomics
Clinical DecisionIntelligence
top related